(thymoglobulin; 2.5 mg/kg, day −2), and TBI (4 Gy). Tacrolimus and mycophenolate mofetil were further used for GVHD prophylaxis. Stable and complete donor chimerism was obtained. On day 30, he only developed grade I aGVHD (stage 1 skin rash). One year later, the number of CD4 + CD25 + CD127-/low Treg cells and CD4 + T cells in his PB remained below the normal range (15/μL and 183/μL, respectively), showing delayed T cell reconstitution. He has been in complete remission (CR) without chronic GVHD for 2 years.
Low-dose thymoglobulin, in addition to its T cell depleting properties, stimulates the recovery of Treg cells [7, 8] . In this regard, Motohashi et al. reported an acute-type ATLL patient who achieved CR following Mog treatment and subsequently received unrelated bone marrow transplantation (uBMT) [9] . Two months after the last Mog administration, uBMT was performed from a serologically two antigen (HLA-C and -DR) mismatched donor by using conditioning with 1.25 mg/kg of thymoglobulin. As a result, they only observed grade I aGVHD.
In ATLL, allo-HSCT at disease regression induced by initial treatment has been shown to improve the clinical outcome [10] . Pretransplant Mog significantly improved the disease status before haplo-PBSCT. Moreover, a recent nationwide study of ATLL patients with pretransplant Mog in Japan showed that pretransplant Mog with intervals of <50 days to allo-HSCT was associated with increased risk of GVHDrelated mortality [6] . In our case, the interval between pretransplant Mog and haplo-PBSCT was 49 days. The nationwide study also pointed out the possibility that in vivo effector T cell depletion with anti-thymocyte globulin contributes to the reduction of severe aGVHD in ATLL patients with 
